Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own targets.
Related Posts
Russia warns U.S. is adding fuel to fire with long-range missile decision
The U.S. decision marks a major reversal in Washington policy a mere two months before the mandate expiry of President Joe Biden
GM, Ford report best annual U.S. sales since 2019
Both General Motors and Ford Motor on Friday reported their best annual U.S. new vehicle sales since 2019.
Netflix and more: Jefferies names stocks set to benefit from a $60 billion anime boom
“Many companies are now positioning anime-related businesses as core to their growth strategies,” Jefferies’ analysts said.